Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

The Finviz API:   Higher Limits, Clearer Data, and More Ways to Connect

Get Started Now
Market News Market Pulse Stocks News ETF News Crypto News

Serina Therapeutics, Inc.

Contributing Author

Recent Articles by Serina Therapeutics, Inc.

Sep-23
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson's Disease: Serina Discusses SER-252's Clinical Progress" SER -5.19% GlobeNewswire
Sep-10
Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference SER SER -11.20% GlobeNewswire
Sep-09
Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson's Disease and Advances to Cohort 2 SER GlobeNewswire
Aug-13
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates SER GlobeNewswire
Jul-24
Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference SER GlobeNewswire
Jul-23
Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease SER GlobeNewswire
Jul-22
Serina Therapeutics Appoints Farrell Simon to its Board of Directors SER GlobeNewswire
Jul-09
Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease SER +10.00% GlobeNewswire
May-14
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates SER +10.26% GlobeNewswire
Apr-07
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit SER GlobeNewswire
Apr-02
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan SER GlobeNewswire
Mar-25
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights SER +24.69% SER -13.86% GlobeNewswire
Mar-24
Serina Therapeutics to Present at the 38th Annual Roth Conference SER -22.86% GlobeNewswire
Mar-18
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease SER SER +93.75% GlobeNewswire
Feb-24
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease SER +6.37% SER +5.99% GlobeNewswire
Feb-19
Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease SER GlobeNewswire
Feb-03
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event SER GlobeNewswire
Jan-28
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease SER SER +30.15% GlobeNewswire
Jan-15
Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity SER SER +15.24% GlobeNewswire
Dec-11
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry SER GlobeNewswire
Dec-10
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program SER GlobeNewswire
Nov-13
Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights SER GlobeNewswire
Nov-03
Serina Therapeutics Provides Regulatory Update on SER-252 Program SER -6.40% GlobeNewswire
Oct-08
Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors SER GlobeNewswire
Oct-06
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease SER GlobeNewswire
Sep-09
Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease SER SER -6.34% GlobeNewswire
Sep-08
Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference SER GlobeNewswire
Aug-25
Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway SER GlobeNewswire
Aug-11
Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights SER -7.44% SER +7.06% GlobeNewswire
Jul-29
Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD) SER GlobeNewswire
Jul-28
Serina Therapeutics to Present at the BTIG Virtual Biotechnology Conference SER +5.83% GlobeNewswire
Jul-10
Serina Therapeutics Makes Grant to New Employee Under Inducement Plan SER GlobeNewswire
Jul-01
Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting SER GlobeNewswire
Jun-23
Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025 SER +5.95% GlobeNewswire
Jun-17
UPDATED: Serina Therapeutics Congratulates Juvenescence Ltd. on $76M First Tranche Close of Series B Funding and Strategic Partnership with M42 SER GlobeNewswire
Jun-17
Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42 SER GlobeNewswire
Jun-09
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event "Is the Beaten Down Biotech Sector the Smartest Bet in Today's Volatile Market?" SER GlobeNewswire
May-22
Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors SER +8.87% GlobeNewswire
May-14
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan SER GlobeNewswire
May-08
Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights SER GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)